Koninklijke Philips N.V. (NYSE: PHG) and Fulgent Genetic (NASDAQ:FLGT) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Koninklijke Philips N.V. and Fulgent Genetic, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Koninklijke Philips N.V. 0 6 5 0 2.45
Fulgent Genetic 0 0 3 0 3.00

Koninklijke Philips N.V. currently has a consensus price target of $33.50, suggesting a potential downside of 19.41%. Fulgent Genetic has a consensus price target of $10.67, suggesting a potential upside of 170.73%. Given Fulgent Genetic’s stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetic is more favorable than Koninklijke Philips N.V..


Koninklijke Philips N.V. pays an annual dividend of $0.73 per share and has a dividend yield of 1.8%. Fulgent Genetic does not pay a dividend. Koninklijke Philips N.V. pays out 42.0% of its earnings in the form of a dividend. Fulgent Genetic has raised its dividend for 4 consecutive years.

Earnings & Valuation

This table compares Koninklijke Philips N.V. and Fulgent Genetic’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Koninklijke Philips N.V. $29.91 billion 1.30 $3.81 billion $1.74 23.89
Fulgent Genetic $20.81 million 3.36 $2.17 million ($0.38) -10.37

Koninklijke Philips N.V. has higher revenue and earnings than Fulgent Genetic. Fulgent Genetic is trading at a lower price-to-earnings ratio than Koninklijke Philips N.V., indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.6% of Koninklijke Philips N.V. shares are held by institutional investors. Comparatively, 16.8% of Fulgent Genetic shares are held by institutional investors. 58.8% of Fulgent Genetic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Koninklijke Philips N.V. and Fulgent Genetic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Koninklijke Philips N.V. 6.39% 8.92% 3.85%
Fulgent Genetic -0.42% -0.02% -0.02%


Koninklijke Philips N.V. beats Fulgent Genetic on 8 of the 15 factors compared between the two stocks.

About Koninklijke Philips N.V.

Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company’s segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

About Fulgent Genetic

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

Receive News & Ratings for Koninklijke Philips N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips N.V. and related companies with MarketBeat.com's FREE daily email newsletter.